Data Infrastructure for Biology
Est 2021|Valuation $500M|Raised $33M
Data Infrastructure for Biology
Published Jul 15, 2026
The vendor states usage metrics (e.g., thousands of scientists and hundreds of biopharma/R&D lab customers). Press coverage in trade outlets indicates recent venture-backed growth. These vendor-reported metrics should be validated during procurement.
| Starting Price | Published per-credit pricing available from the vendor (pay-as-you-go); vendor provides example scenarios | Pricing typically via enterprise contracts + cloud usage; not listed as a single public number | Costs align with underlying cloud usage; guidance focuses on billing mechanics rather than a single public plan price |
| Best Fit | Techbio teams and solution providers needing white-labeled portals, managed workflows, and hosted notebooks/pods | Enterprises requiring mature governance for clinical genomics and precision health | Teams using WDL/Broad ecosystem and GCP-native biomedical workflows |
| Key Strengths | Unit pricing model with published examples; white-label delivery options; integrated compute and workflow execution | Enterprise maturity, established procurement presence, regulatory footprint | Integration with Broad workflows, community resources, and GCP billing transparency |
| Key Weaknesses | Limited visibility on third-party reviews; many public claims are vendor-published; data residency and SSO specifics not clearly documented publicly | Perceptions of vendor lock-in and potentially high contract costs for some customers | Cloud cost management can be complex; setup can be complex for some users |
—